New Digital Insurance Research Reveals How Firms are Deploying AI, What They're Getting in ROI and How Strategies are Evolving
NEW YORK, NY / / July 1, 2025 / Digital Insurance, a leading information resource for executives and innovators in the insurance sector, releases its latest research report, The Cost of AI: The AI Revolution Gathers Steam. Sponsored by Salesforce, the findings reveal adoption of artificial intelligence is rising in the insurance industry, with more than half expecting to implement it within 12 to 18 months - and many already seeing returns.
AI is moving from pilot project to enterprise strategy for some organizations, with a growing number of companies already seeing returns on their investments. But as AI deployments scale, so do the price tags - and industry professionals may face tough choices about how to modernize, budget and prioritize.
The research offers fresh insight into how industry organizations are implementing AI, what they're prioritizing and what's standing in the way of broader success. Based on proprietary research with professionals across the insurance industry, the report reveals how different types of organizations are navigating this next phase of transformation.
Key takeaways include:
Where companies are finding the most value from their AI investments - and where results are falling short
What's driving organizations to move faster and what's holding others back
How generative AI is reshaping the conversation around customer experience
What companies are spending now and how that's expected to shift in the year ahead
"AI investments are already paying off, particularly for firms that have implemented them aggressively to improve efficiency," says Janet King, SVP, Content Strategy, Research at Arizent, parent company of Digital Insurance. "At this point in the adoption curve, the most advanced companies appear to see more opportunities to reap positive returns, suggesting those at the leading edge could remain in that position for some time."
The data indicates nearly all organizations expect their AI spending to increase to some extent over the next 12 months. Only a few companies expect their spending to remain level or decrease. Organizations that trail their peers will need to accelerate their strategies as much as possible or risk falling further behind as early adopters continue to expand their capabilities.
To explore the full findings and see where your organization stands, download the full report: https://www.americanbanker.com/payments/news/embedded-payments-demand-comes-from-health-care-travel
About Digital Insurance
Digital Insurance is the essential resource for senior executives leading the digital transformation of the insurance industry. Across events and member forums, original research reports and editorial news and analysis, Digital Insurance examines business-critical topics in technology innovation, data advancements, insurtech market trends and transformation strategies. The brand convenes the community around these ideas and insights so they can understand the real-world impact on their firms and the customers they serve.
About Arizent
Arizent is a business information company that advances professional communities by providing insights and analysis and convening industry leaders. The company uses deep industry expertise and a data-driven platform to deliver its services, which include subscriptions, marketing services, live events and access to Leaders Forum, a digital content platform featuring livestream and on-demand formats. Arizent also connects business communities through leading financial services brands like American Banker, The Bond Buyer, Financial Planning and National Mortgage News, as well as professional services brands like Accounting Today, Employee Benefit News and Digital Insurance.
About Salesforce
Salesforce is the #1 AI CRM, helping companies connect with customers in a whole new way since 1999. Our product portfolio, Agentforce, brings #1 CRM apps together with trusted AI and data on one integrated platform so companies can grow relationships, productivity, and their bottom line. Salesforce helps insurance firms lower operational costs, grow efficiently, innovate at scale, and personalize customer experiences. With Salesforce, insurance carriers, agencies, and brokerages can connect and empower their entire organization, spanning Marketing, Sales, Service, Data, IT, and Analytics. Our AI-driven, connected platform empowers insurers and their distribution partners to manage all core operations from one system - including product development, quoting, claims, and more.
Contact Details
Arizent
Janet King
+1 207-807-4806
janet.king@arizent.com
Company Website
https://www.arizent.com/
SOURCE: Arizent
View the original press release on ACCESS Newswire
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely
Explore BridgeBio Oncology Therapeutics's Fair Values from the Community and select yours Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should BridgeBio Oncology Therapeutics (NASDAQ:BBOT) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How Long Is BridgeBio Oncology Therapeutics' Cash Runway? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at December 2024, BridgeBio Oncology Therapeutics had cash of US$156m and no debt. In the last year, its cash burn was US$55m. That means it had a cash runway of about 2.8 years as of December 2024. That's decent, giving the company a couple years to develop its business. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for BridgeBio Oncology Therapeutics How Is BridgeBio Oncology Therapeutics' Cash Burn Changing Over Time? Because BridgeBio Oncology Therapeutics isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 4.9% in the last year, it seems that the company is ratcheting up investment in the business over time. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. How Hard Would It Be For BridgeBio Oncology Therapeutics To Raise More Cash For Growth? Since its cash burn is increasing (albeit only slightly), BridgeBio Oncology Therapeutics shareholders should still be mindful of the possibility it will require more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. BridgeBio Oncology Therapeutics has a market capitalisation of US$921m and burnt through US$55m last year, which is 6.0% of the company's market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. Is BridgeBio Oncology Therapeutics' Cash Burn A Worry? As you can probably tell by now, we're not too worried about BridgeBio Oncology Therapeutics' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. On another note, BridgeBio Oncology Therapeutics has 5 warning signs (and 3 which are concerning) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 hours ago
- Yahoo
Here's Why We're Not At All Concerned With RecycLiCo Battery Materials' (CVE:AMY) Cash Burn Situation
Explore RecycLiCo Battery Materials's Fair Values from the Community and select yours There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. Given this risk, we thought we'd take a look at whether RecycLiCo Battery Materials (CVE:AMY) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. How Long Is RecycLiCo Battery Materials' Cash Runway? A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. As at April 2025, RecycLiCo Battery Materials had cash of CA$16m and no debt. Looking at the last year, the company burnt through CA$1.4m. That means it had a cash runway of very many years as of April 2025. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for RecycLiCo Battery Materials How Is RecycLiCo Battery Materials' Cash Burn Changing Over Time? RecycLiCo Battery Materials didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Even though it doesn't get us excited, the 48% reduction in cash burn year on year does suggest the company can continue operating for quite some time. Admittedly, we're a bit cautious of RecycLiCo Battery Materials due to its lack of significant operating revenues. We prefer most of the stocks on this list of stocks that analysts expect to grow. How Hard Would It Be For RecycLiCo Battery Materials To Raise More Cash For Growth? Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for RecycLiCo Battery Materials to raise more cash in the future. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. RecycLiCo Battery Materials has a market capitalisation of CA$32m and burnt through CA$1.4m last year, which is 4.4% of the company's market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan. How Risky Is RecycLiCo Battery Materials' Cash Burn Situation? It may already be apparent to you that we're relatively comfortable with the way RecycLiCo Battery Materials is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. And even its cash burn reduction was very encouraging. After considering a range of factors in this article, we're pretty relaxed about its cash burn, since the company seems to be in a good position to continue to fund its growth. Taking a deeper dive, we've spotted 4 warning signs for RecycLiCo Battery Materials you should be aware of, and 3 of them make us uncomfortable. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
6 hours ago
- Yahoo
These 3 Artificial Intelligence (AI) Stocks Could Soar 45% or More Over the Next 12 Months, According to Wall Street
Key Points Rapid uptake of new AI tools has analysts thinking Salesforce stock can rocket higher over the next 12 months. Shares of beaten-down HubSpot are expected to climb by 59% from a recent closing price. Fear of a slowdown has been tough on stock price, but it isn't slowing down by much. 10 stocks we like better than Salesforce › Don't let your own disappointing experiences with artificial intelligence (AI) applications fool you into thinking this rapidly growing industry can't produce real earnings. This year alone, the big four tech firms Amazon, Meta, Alphabet, and Microsoft told investors they'd spend a cumulative $364 billion in 2025 on AI-related infrastructure. Analysts on Wall Street have been telling anyone who'll listen that Big Tech's spending habits suggest big gains ahead for a handful of lesser-known AI-focused businesses. According to consensus estimates, shares of Salesforce (NYSE: CRM), HubSpot (NYSE: HUBS), and (NASDAQ: MNDY), could soar 30% or more over the next 12 months. 1. Salesforce Financial data provider LSEG surveyed 54 analysts in August who cover Salesforce, the leading customer relationship management (CRM) software business. Forty-two rated the stock a "buy" or "strong buy." The remaining 10 recommended holding the stock. In addition to calling the stock a buy, most investment bank analysts on Wall Street have high expectations for Salesforce's future. The consensus price target for Salesforce implies a gain of 45% over the next 12 months. The most enthusiastic analyst following the CRM software provider thinks the stock could rocket 84% higher. Analysts who follow the stock are encouraged by an agreement announced in May to acquire AI-powered cloud data management company Informatica. Investors, on the other hand, have more reservations about the $8 billion investment. On Aug. 15, the stock was down 33% from the peak it set in February. Salesforce's stock price has been under pressure, but its underlying business is strong. During its fiscal first quarter that ended April 30, sales rose 8% year over year. The company's Data Cloud and AI segment is leading the way with annual recurring revenue that soared more than 120% year over year. 2. HubSpot Wall Street analysts are also pounding the table on HubSpot and its AI-powered customer platform that helps businesses manage marketing, sales, service, and operations in a single, unified system. Out of 36 analysts surveyed in August, 33 labeled it a "strong buy" or at least a "buy." There were no sell or hold recommendations. Investment bank analysts expect HubSpot stock to rocket higher. The consensus price target on the stock is $695.80, or 59% above the stock's price on Aug. 15. HubSpot shareholders could use the bump that Wall Street analysts have predicted. The stock is down about 47% from a peak it reached in February. Investors were disappointed with first-quarter revenue per user that shrank by 4% year over year. In the second quarter, revenue per customer returned to growth, but the 1% gain wasn't particularly encouraging. HubSpot's per-user revenue figures haven't been thrilling, but the overall business is growing at an impressive pace thanks to the company's AI-first focus. Total customers at the end of June grew by 18% year over year to 267,982, and management expects total sales to climb 17% in 2025. According to CEO Yamini Rangan, "embedded AI features are helping go-to-market teams work smarter and faster." 3. Investment bank analysts have also been encouraging everyday investors to consider the work management platform provider. Among 25 analysts surveyed, 24 recommend the stock with a "strong buy" or "buy" rating. None of the analysts surveyed issued hold or sell recommendations. Among the experts who follow expectations for the stock's future performance are sky high. The consensus price target on the stock implies a 61% gain over the next 12 months. Everyday investors aren't as enamoured with as the analysts who follow the stock. Shares have fallen 46% from a peak they set in February. The stock was hammered recently after management issued a relatively soft revenue outlook. Third-quarter sales are expected to rise by 24% to 25% year over year, which is a significant deceleration from sales that rocketed 33% higher in 2024. Revenue growth is softening at but it's hardly anything to complain about. Management expects total sales to rise by 26% this year to $1.2 billion, and the gains could continue. In the second quarter alone, the company introduced three new AI-powered capabilities to boost its customers' speed and productivity. Should you invest $1,000 in Salesforce right now? Before you buy stock in Salesforce, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Salesforce wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Cory Renauer has positions in Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, HubSpot, Meta Platforms, Microsoft, and Salesforce. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. These 3 Artificial Intelligence (AI) Stocks Could Soar 45% or More Over the Next 12 Months, According to Wall Street was originally published by The Motley Fool
